公开(公告)号：US07998474B2

公开(公告)日：2011-08-16

申请号：US10285224

申请日：2002-10-31

申请人： Denise Kelly

发明人： Denise Kelly

IPC分类号： A61K35/74 ,  A61P29/00

CPC分类号： G01N33/6863 ,  A61K31/02 ,  A61K35/74 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2500/00

摘要： The invention relates to an assay to select a candidate drug for the treatment of inflammatory disease due to cytokine production. The assay comprises: a) exposing said candidate drug to intestinal cells; and b) analysing the effect of the said candidate drug selected from the group consisting of the variation of nuclear export or import of transcription factors from the NF-κB family the disruption of transcriptional activity of transcription factors from the NF-κB family, the differential histone acetylation of p65 (RelA); the variation of the amount of PPARγ/RelA complexes in the cytosol of the cells; and a combination thereof. The invention further relates to methods for the treatment of inflammatory cytokine production associated diseases and to the use of a therapeutically effective dose of Bacteroides thetaiotaomicron or a component thereof.

摘要翻译： 本发明涉及一种选择用于治疗由于细胞因子产生引起的炎性疾病的候选药物的测定法。 该测定包括：a）将所述候选药物暴露于肠细胞; 和b）分析所选候选药物的作用，所述药物选自核出口的变异或来自NF-κB家族的转录因子的导入，转录因子从NF-κB的转录活性的破坏 家族，差异组蛋白乙酰化p65（RelA）; PPARγ/ RelA复合物在细胞质中的量的变化; 及其组合。 本发明还涉及用于治疗炎性细胞因子产生相关疾病的方法，以及使用治疗有效剂量的拟杆菌属或其组分。

公开(公告)号：US06277813B1

公开(公告)日：2001-08-21

申请号：US08983537

申请日：1998-07-29

申请人： Denise Kelly

发明人： Denise Kelly

IPC分类号： C07K14475

CPC分类号： C07K14/475 ,  A61K38/00

摘要： The present invention relates to a polypeptide growth factor derived from colostrum (CDGF) having defined chemical and biological characteristics. The factor may be prepared from porcine or bovine colostrum and pharmaceutical uses thereof may include combatting invasion of the body by pathogens, wound healing, promoting organ growth and development and promoting adaption of the gastrointestinal tract to diet change.

摘要翻译： 本发明涉及源自具有确定的化学和生物特征的初乳​​（CDGF）的多肽生长因子。 该因子可以由猪或牛初乳制备，其药学用途可以包括通过病原体侵袭身体，伤口愈合，促进器官生长和发育，促进胃肠道适应饮食改变。

公开(公告)号：US09539293B2

公开(公告)日：2017-01-10

申请号：US14232475

申请日：2012-07-13

申请人： Denise Kelly

发明人： Denise Kelly

IPC分类号： A61K35/74 ,  A61K35/747 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  C12N1/20

CPC分类号： A61K35/747 ,  A23K10/18 ,  A23L33/135 ,  A23V2002/00 ,  C12N1/20 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  Y02A50/473 ,  Y02A50/481

摘要： Described herein are porcine lactic acid bacterial strain compositions and processes of obtaining porcine lactic acid bacterial strains. Further aspects of the invention relate to food additives, supplements and probiotic compositions comprising said bacterial strains, and therapeutic uses of said bacterial strain compositions.

摘要翻译： 本文描述的是猪乳酸菌株组合物和获得猪乳酸菌菌株的方法。 本发明的其它方面涉及包含所述细菌菌株的食品添加剂，补充剂和益生菌组合物以及所述细菌菌株组合物的治疗用途。

公开(公告)号：US20210350905A1

公开(公告)日：2021-11-11

申请号：US17308829

申请日：2021-05-05

申请人： Katharine Denise Kelly

发明人： Katharine Denise Kelly

IPC分类号： G16H20/70 ,  G16H10/60 ,  G16H50/20 ,  G16H40/67

摘要： A computer-implemented method of formulating a holistic treatment recommendation. The method includes receiving a first set of patient data based on responses to a first set of prompts relating to a plurality of priority concern areas associated with self-care management and determining, using a first algorithm, which of the priority concern areas are relevant to the patient. The method further includes receiving a second set of patient data based on responses to a second set of prompts relating to the one or more of the priority concern areas determined to be relevant to the patient and determining, using a second algorithm, which of the priority concern areas is most relevant to the patient. The method further includes synthesizing and analyzing the second set of patient data and the patient's electronic medical health data to determine a holistic treatment recommendation for the patient, which is then output on a display.

公开(公告)号：US20150050254A1

公开(公告)日：2015-02-19

申请号：US14232475

申请日：2012-07-13

申请人： Denise Kelly

发明人： Denise Kelly

IPC分类号： A61K35/74 ,  A23L1/30 ,  A23K1/00 ,  C12R1/225 ,  C12N1/20

CPC分类号： A61K35/747 ,  A23K10/18 ,  A23L33/135 ,  A23V2002/00 ,  C12N1/20 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  Y02A50/473 ,  Y02A50/481

摘要： A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.

摘要翻译： 本发明的第一方面涉及一种猪乳酸菌株，其中所述细菌菌株的特征在于以下一个或多个特征：（i）对大肠杆菌表现出抗微生物活性的能力; （ii）对肠炎沙门氏菌具有抗菌活性的能力; （iii）抑制由12-0-十四碳酰吗啡酚-13-乙酸酯（PMA）诱导的IPEC细胞炎症的能力; （iv）阻断肠炎沙门菌的IPEC细胞附着或侵入的能力; （v）阻断大肠杆菌对IPEC细胞的附着或侵入的能力; （vi）对一种或多种选自以下的抗生素没有抗生素抗性：氨苄青霉素; 头孢噻肟 氯霉素 红霉素; 庆大霉素 四环素; 万古霉素 甲硝唑 萘啶酸 和卡那霉素; 和（vii）当进行三个加热循环时表现出热稳定性的能力，每个循环包括在70℃的温度下加热15分钟。 本发明的其它方面涉及包含所述细菌菌株的组合物和所述细菌菌株的治疗用途。